M. Davis

发表

10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.

David Gillatt, Richard M Martin, John Staffurth, 2017, The New England journal of medicine.

The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancer

T. Peters, J. Oxley, F. Hamdy, 2020, British Journal of Cancer.

Predicting High-Grade Cancer at Ten-Core Prostate Biopsy Using Four Kallikrein Markers Measured in Blood in the ProtecT Study

P. Scardino, F. Hamdy, D. Neal, 2015, Journal of the National Cancer Institute.

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study

Chris Metcalfe, Freddie C Hamdy, Jenny L Donovan, 2012, BMJ : British Medical Journal.

Post-diagnosis serum insulin-like growth factors in relation to dietary and lifestyle changes in the Prostate testing for cancer and Treatment (ProtecT) trial

F. Hamdy, D. Neal, J. Donovan, 2017, Cancer Causes & Control.

Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT.

T. Peters, J. Oxley, F. Hamdy, 2020, Health technology assessment.

Investigating the prostate specific antigen, body mass index and age relationship: is an age–BMI-adjusted PSA model clinically useful?

Jenny Donovan, Sean Harrison, Richard M Martin, 2016, Cancer Causes & Control.

Patient‐reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life

Joyce E. Wilkinson, T. Peters, P. Fayers, 2016, BJU international.

Predictors of attendance for prostate-specific antigen screening tests and prostate biopsy.

F. Hamdy, D. Neal, J. Donovan, 2012, European urology.

Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial.

T. Peters, F. Hamdy, D. Neal, 2014, The Lancet. Oncology.

A prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial

T. Peters, J. Oxley, F. Hamdy, 2017, Journal of clinical epidemiology.

Height and Prostate Cancer Risk: A Large Nested Case-Control Study (ProtecT) and Meta-analysis

Ross J. Harris, F. Hamdy, D. Neal, 2008, Cancer Epidemiology Biomarkers & Prevention.

Associations of Lifestyle Factors and Anthropometric Measures with Repeat PSA Levels During Active Surveillance/Monitoring

F. Hamdy, D. Neal, J. Donovan, 2012, Cancer Epidemiology, Biomarkers & Prevention.

Association of Folate-Pathway Gene Polymorphisms with the Risk of Prostate Cancer: a Population-Based Nested Case-Control Study, Systematic Review, and Meta-analysis

K. Stefánsson, J. Morrison, P. Sulem, 2009, Cancer Epidemiology, Biomarkers & Prevention.

Strategies adopted by men to deal with uncertainty and anxiety when following an active surveillance/monitoring protocol for localised prostate cancer and implications for care: a longitudinal qualitative study embedded within the ProtecT trial

T. Peters, F. Hamdy, D. Neal, 2020, BMJ Open.

Patient-Reported Outcomes 12 Years after Localized Prostate Cancer Treatment.

J. Oxley, F. Hamdy, D. Neal, 2023, NEJM evidence.

Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received.

T. Peters, P. Fayers, D. Aston, 2019, European urology.

Men with prostate cancer make positive dietary changes following diagnosis and treatment

F. Hamdy, D. Neal, J. Donovan, 2013, Cancer Causes & Control.

Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial

J. Oxley, F. Hamdy, D. Neal, 2017, European urology.

Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.

J. Oxley, F. Hamdy, D. Neal, 2023, The New England journal of medicine.

Associations between an Obesity Related Genetic Variant (FTO rs9939609) and Prostate Cancer Risk

Jenny Donovan, Angela Cox, Sarah J. Lewis, 2010, PloS one.

A cross-sectional analysis of the association between diet and insulin-like growth factor (IGF)-I, IGF-II, IGF-binding protein (IGFBP)-2, and IGFBP-3 in men in the United Kingdom

F. Hamdy, D. Neal, J. Donovan, 2012, Cancer Causes & Control.

Association of diabetes mellitus with prostate cancer: Nested case–control study (Prostate testing for cancer and Treatment study)

F. Hamdy, D. Neal, J. Donovan, 2011, International journal of cancer.

Genetic Variants in the Vitamin D Receptor Are Associated with Advanced Prostate Cancer at Diagnosis: Findings from the Prostate Testing for Cancer and Treatment Study and a Systematic Review

David M. Evans, D. Lawlor, F. Hamdy, 2009, Cancer Epidemiology, Biomarkers & Prevention.

The causal roles of vitamin B(12) and transcobalamin in prostate cancer: can Mendelian randomization analysis provide definitive answers?

F. Hamdy, D. Neal, J. Donovan, 2011, International journal of molecular epidemiology and genetics.

Very low PSA concentrations and deletions of the KLK3 gene.

F. Hamdy, D. Neal, J. Donovan, 2013, Clinical chemistry.

The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression

J. Oxley, M. Varma, F. Hamdy, 2020, BJU international.

A comparison of socio-demographic and psychological factors between patients consenting to randomisation and those selecting treatment (the ProtecT study).

T. Peters, J. Sterne, F. Hamdy, 2006, Contemporary clinical trials.

Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study)

D. Aston, J. Oxley, F. Hamdy, 2022, BJU international.

Development of a new method for monitoring prostate-specific antigen changes in men with localised prostate cancer: a comparison of observational cohorts.

Hans Garmo, Richard M Martin, Chris Metcalfe, 2010, European urology.

a copy of Development of a new method for monitoring prostate-specific antigen changes in men with localised prostate cancer: A comparison of observational cohorts . method for monitoring prostate-specific localised

L. Holmberg, F. Hamdy, J. Donovan, 2019 .

Insulin-like growth factors (IGFs) and IGF-binding proteins in active monitoring of localized prostate cancer: a population-based observational study

F. Hamdy, D. Neal, J. Donovan, 2012, Cancer Causes & Control.

Circulating Folate, Vitamin B12, Homocysteine, Vitamin B12 Transport Proteins, and Risk of Prostate Cancer: a Case-Control Study, Systematic Review, and Meta-analysis

Ross J. Harris, F. Hamdy, D. Neal, 2010, Cancer Epidemiology, Biomarkers & Prevention.

Patient‐reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life

Joyce E. Wilkinson, T. Peters, P. Fayers, 2016, BJU international.

Factors associated with trial recruitment, preferences and treatments received were elucidated in a comprehensive-cohort study.

T. Peters, F. Hamdy, D. Neal, 2019, Journal of clinical epidemiology.

the ProtecT Study Group (2019). Factors associated with trial recruitment, preferences, and treatments received were elucidated in a comprehensive cohort study. Journal of Clinical Epidemiology, 113, 200-213.

F. Hamdy, J. Lane, G. Young, 2022 .

Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial

J. Oxley, F. Hamdy, J. Donovan, 2017, European urology.

Associations of Folate, Vitamin B12, Homocysteine, and Folate-Pathway Polymorphisms with Prostate-Specific Antigen Velocity in Men with Localized Prostate Cancer

F. Hamdy, D. Neal, J. Donovan, 2010, Cancer Epidemiology, Biomarkers & Prevention.

Associations of lower urinary tract symptoms with prostate‐specific antigen levels, and screen‐detected localized and advanced prostate cancer: a case‐control study nested within the UK population‐based ProtecT (Prostate testing for cancer and Treatment) study

F. Hamdy, D. Neal, J. Donovan, 2008, BJU international.